Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MENS
MENS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MENS News
Jyong Biotech's Strategic Vision for Plant-Derived Therapies
1d ago
Newsfilter
Jyong Biotech Releases Annual Report for 2025
May 15 2026
Newsfilter
Jyong Biotech Advances Market Access Strategies for Plant-Based Drugs
Apr 28 2026
Newsfilter
Jyong Biotech Updates on MCS®-2 Clinical Progress
Mar 27 2026
Newsfilter
Jyong Biotech Reports Clinical Progress and Market Strategy
Feb 13 2026
Yahoo Finance
Jyong Biotech Achieves Milestone with MCS-8 Phase II Trial Success
Feb 12 2026
Newsfilter
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
Jan 02 2026
Benzinga
FuelCell Energy Files for $200 Million Stock Offering, Shares Drop 8.9%
Dec 31 2025
Benzinga
Axsome Therapeutics Plans New Drug Application for AXS-12 in January, Shares Surge 16.1%
Dec 31 2025
Benzinga
Sidus Space Prices Public Offering at $1.30 per Share
Dec 23 2025
Benzinga
U.S. Stocks Rise with Nasdaq Gaining Over 100 Points
Dec 22 2025
Benzinga
Jyong Biotech Experiences Share Price Fluctuation Post Lock-Up Expiry
Dec 19 2025
Globenewswire
Jyong Biotech Experiences Share Price Fluctuation Post Lock-Up Expiry
Dec 19 2025
Newsfilter
Jyong Biotech Stock Reaches Oversold Status (MENS)
Dec 10 2025
NASDAQ.COM
Major Stocks Including Leggett & Platt, New Fortress Energy, and Bausch Health Companies Rise on Monday
Dec 01 2025
Benzinga
Jyong Biotech Signs LOI with Korean Firm to Explore MCS-2 Drug Development
Nov 24 2025
Newsfilter
Show More News
